Adjectives such as ground-breaking and game-changing have greeted the detailed results of the closely watched EMPEROR-Preserved trial of Boehringer Ingelheim GmbH and Eli Lilly and Company's Jardiance, with investigators stating that the SGLT2 inhibitor is the first drug to show "unequivocal benefit" on major harmful outcomes in patients with heart failure and a preserved ejection fraction (HFpEF).
The results from the 5,988-patient study, the highlight of the virtual European Society of Cardiology meeting, showed that Jardiance (empagliflozin)...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)